alphaKlothoLR

What α-Klotho is: the body's own protein. α-Klotho (gene KL, UniProt Q9UEF7) is a membrane protein of 1,012 amino acids, expressed in the kidney and the parathyroid glands. Its large outer portion, two domains called KL1 and KL2, can be cut free from the cell and circulates in blood, urine and cerebrospinal fluid as “soluble klotho” (Hu 2013, review).

It was discovered in 1997, when mice with a defect in the gene developed a syndrome resembling human ageing: short lifespan, infertility, arteriosclerosis, skin atrophy, osteoporosis and emphysema (Kuro-o 1997, mouse). In 2005 the same group reported that mice engineered to overproduce it lived longer, and proposed that it acts as a circulating hormone that dampens insulin and IGF-1 signalling (Kurosu 2005, mouse).

Its best-characterised job is in mineral metabolism. α-Klotho converts a common growth-factor receptor, FGFR1c, into the receptor for FGF23, the bone hormone that tells the kidney to excrete phosphate (Urakawa 2006, mouse and cell studies). In mice, Klotho in the kidney also acts directly on the tubule's phosphate transporter (Hu 2010, mouse and cell studies).

A 2018 crystal structure showed how the co-receptor works: the shed outer portion holds FGF23 and its receptor together as a scaffold (Chen 2018, structural study).

The enzyme question is contested. It matters here because the product page presents it as settled. α-Klotho's two domains resemble sugar-cutting enzymes (glycosidases), and cell and test-tube studies reported that it can act like one.

Tohyama 2004 found β-glucuronidase activity in a Klotho protein fused to an antibody fragment (in vitro), and Cha 2008 found it removes sialic acid in a way that keeps the TRPV5 calcium channel on the cell surface (cultured cells). The 2018 structure argues the other way: its authors conclude that α-Klotho's structure is “incompatible with its purported glycosidase activity,” and that it works as a non-enzymatic scaffold (Chen 2018).

β-Klotho is a different protein. β-Klotho (gene KLB) is a related co-receptor for two other hormones, FGF19 and FGF21, and is expressed in the liver and fat (Hu 2013, review). It is not α-Klotho, it is not what this product claims to contain, and evidence about one is not evidence about the other.

One of the references on the product page is a structural study of β-Klotho (Kuzina 2019).

What is known in people is observational. In one Italian cohort, older adults with lower blood klotho had weaker grip strength.

The association held only below a threshold of 681 pg/mL, which covered about half the cohort, and klotho was measured once (Semba 2012, human, observational). A variant of the KLOTHO gene, KL-VS, was associated with better cognition in people carrying one copy, and mice engineered to overproduce klotho did better on learning and memory tests (Dubal 2014, human genetics plus mouse).

Associations like these cannot show that giving klotho would change anything. No klotho protein has been given to a person under the skin, into a muscle or into a vein in a study indexed in PubMed or registered on ClinicalTrials.gov.

The human studies PubMed indexes applied klotho-protein skin products to the face (Humble 2025, 16 participants, one serum; Yoelin 2026, 16 participants, a three-product regimen of face serum, eye serum and night cream). In the second, the maker supplied the products and paid for the medical writing, the statistics and the publication charges, and its chief executive is an author.

Yoelin 2026 also cites an earlier ten-case clinical experience in facial photoaging (Humble and Mendiola, Journal of Aging Science, 2022). Neither PubMed nor Europe PMC indexes it, and we could not obtain it, so we cannot say what it applied or by what route.

The nearest injected experiment is in monkeys. After validating the rhesus form of the protein in mice, researchers found that a single low dose improved memory in aged rhesus monkeys and a higher dose did not (Castner 2023, rhesus macaque).

That was native rhesus klotho, not an albumin-binding construct, and the dose-response ran the wrong way for anyone hoping more would help.

What the seller says about this construct, and what we could check. BioLongevity Labs describes alphaKlothoLR as carrying a 29-amino-acid albumin-binding peptide and claims “strong albumin binding affinity (<20 nM)”, “native FGF23 binding activity (15-30 nM)”, “optimized: 16.2 nM”, and “cellular activity up to 19 days.”

We found no publication about the construct. PubMed, and Europe PMC (which also indexes preprints and patents), return nothing for the product name or for the tail's sequence (searched 16 October 2026).

The figures trace instead to a US patent granted in August 2025 to an individual inventor, with no company named as assignee: US 12,377,158 B1, “Enhanced peptide constructs for albumin binding.” The product page does not cite it, and we could not confirm any link between it and the seller.

The tail is that patent's SEQ ID NO: 4. “Less than 20 nanomolar” is the wording of its first claim, and 15 to 30 nM and 16.2 nM binding to FGF23 are its fourth and fifth claims.

Claims define what a patent covers; they are not measurements. The patent shows data from exactly one experiment, a surface plasmon resonance run with human albumin immobilised and mouse klotho protein as the analyte, reported at 7.94 nM.

The patent says that run used embodiments of its technology, but its sample table names the analyte only as “Mouse klotho”, at 108,000 Da, and nothing in the description says the analyte carried the tail or the linker. The run measured binding to albumin, not to FGF23, so nothing in the patent supports the two FGF23 figures.

The tail itself is not new. Its business end, SA21, comes from a 2002 Genentech study that measured its affinity for human albumin at about 467 nM (Dennis 2002), roughly twenty-three times weaker than “<20 nM.”

The patent credits the difference to the added glycine–serine linker but shows no measurement of it. As for “up to 19 days,” the patent asserts that proteins bound to its tail have a human half-life of about 19 days, which is the half-life of albumin itself (Zorzi 2019, review), and shows no experiment.

The same tail and the same “<20 nM” appear on this seller's FLGR-242 product page.

The molecular-weight figures are inconsistent. The product page gives “α-Klotho protein (1012 amino acids)” plus the tail, at “~133-135 kDa.” 1,012 residues is the full-length human precursor in UniProt.

That count includes a 33-residue signal sequence that the cell removes, and the stretch that anchors the protein in the membrane, which a soluble product would not normally carry. By amino-acid arithmetic, the precursor weighs about 116.2 kDa, or about 119.1 kDa with the tail.

The shed outer portion alone (residues 34 to 981) is about 109 kDa, or about 112 kDa with the tail. The page's 133–135 kDa can be reached only with additions the page does not describe, most plausibly sugar chains: α-Klotho has seven annotated N-glycosylation sites.

The table does not state the construct's actual makeup.

What the certificates show. Two certificates of analysis circulate for this product.

Both were issued by MDx BioAnalytical Laboratory to BioLongevity Labs, and both are linked from the product page: COA260086 (sample received 7 January 2026) and COA260797 (received 18 February 2026). Each reports a labelled quantity, a measured content close to it, purity above 99.7 percent and an endotoxin pass.

Like the certificates for this vendor's FLGR-242, they measure purity and quantity, not identity. The “determined identification” restates the label supplied with the sample, and there is no reference standard, no stated molecular weight, no sequence, and no mention of the albumin binder, the linker or long release.

The two certificates also disagree with each other and with the product page. The two certificates label the vials “a-Klotho MAB” and “a-KLOTHO-MAB”, a term neither document defines; in biochemistry “mAb” usually means a monoclonal antibody, a different kind of molecule from the protein the product page describes.

COA260086 records its batch number as the product code “KLOTHO” and its determined identity as plain “a-Klotho.” COA260797 has no batch field, and its CAS-number box holds a number that is not a valid CAS registry number and has the same format as this vendor's FLGR-242 batch numbers.

The mass-spectrometry panels of the two batches, received six weeks apart, carry the same six annotated peaks. Read at their own charge labels, those peaks imply masses from about 133 to 139 kDa rather than one mass, so the panels leave the molecular weight unestablished too.

Neither certificate tested sterility, and an endotoxin pass is not a sterility test.

The product page's reading list. The page's “Klotho Research” section cites 31 papers.

We looked up every one in PubMed through NCBI's E-utilities and read each abstract, and the full text wherever it is openly available. None studies this construct or any albumin-binding klotho.

Most are about the body's own α-Klotho in mice or cultured cells, twelve are tagged as reviews in PubMed and two more are review-style pieces, and the only study of people among them is one observational association (Semba 2012). Several are attached to sentences they fail to support.

A paper whose title states that Klotho lacks a vitamin-D-independent role in glucose homeostasis is cited for Klotho boosting insulin secretion (Anour 2012). A structural study of β-Klotho, a different protein, is cited for α-Klotho's enzyme sites (Kuzina 2019).

A study reporting β-glucuronidase activity is cited for sialidase activity (Tohyama 2004), and a study of ammonium chloride in klotho-deficient mice, which reports that it prevented tissue calcification, is cited for nitric-oxide signalling in endothelial cells (Leibrock 2015). A run of citations appears shifted by one place: the insulin-secretion finding is in the paper numbered after the one cited for it (Lin & Sun 2012), and that paper's own citation is attached to a liver finding, while its own report is in a mouse insulin-secreting cell line.

One muscle study is cited for a progenitor-cell finding while its headline result goes unmentioned: klotho's effect was biphasic and age-dependent, helping old mice but not the oldest (Clemens 2021). A reading list of genuine klotho biology is not evidence about this product.

What would establish what is in the vial: a certificate that states the expected intact mass and shows a measured mass that matches it, plus a peptide map or sequence coverage showing both the klotho portion and the tail. Before any of it could mean anything for a person, there would also need to be a published study.

None of these exists.